The Use of an Inhaled Salt Solution to Treat Viral Lung Infections in Infants.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00151905|
Recruitment Status : Completed
First Posted : September 9, 2005
Last Update Posted : May 7, 2007
|Condition or disease||Intervention/treatment||Phase|
|Bronchiolitis||Drug: 3 % hypertonic saline||Phase 2 Phase 3|
Bronchiolitis is a common illness in infants and is associated with a significant morbidity. Standard therapy is controversial and largely ineffective; care is mostly supportive although nebulized medications continue to be commonly used. These medications are typically mixed with normal saline to produce a sufficient volume for efficient nebulization.
Inhaled hypertonic saline has been used to aid airway clearance in children with cystic fibrosis. It has also been used, in low dose, in two small studies in children with bronchiolitis. The current study is a randomized, double-blind, placebo-controlled, multi-center trial comparing frequent dosing with 3% hypertonic saline compared to normal saline in the treatment of infants hospitalized with bronchiolitis.
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Nebulized Hypertonic Saline in the Treatment of Bronchiolitis in Infants|
|Study Start Date :||November 2003|
|Study Completion Date :||September 2006|
- Length of stay.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00151905
|Canada, British Columbia|
|Victoria General Hospital|
|Victoria, British Columbia, Canada|
|Kingston General Hospital|
|Kingston, Ontario, Canada, K7L 2V7|
|United Arab Emirates|
|Sheikh Khalifa Medical City|
|Abu Dhabi, United Arab Emirates, 51900|
|Principal Investigator:||Brian A Kuzik, MD, FRCP||Sheikh Khalifa Medical City|